CVS Health announced the initiation of a clinical trial designed to evaluate the safety and efficacy of the HemoCare Hemodialysis System for administration of home hemodialysis. The innovative device includes safety features and is designed to make home hemodialysis simple for health care consumers. Home hemodialysis helps facilitate longer, more frequent dialysis treatments as compared to in-center treatments, and published clinical research has found that longer, more frequent hemodialysis treatments result in better health outcomes in appropriate populations. The clinical trial of up to 70 individuals will be conducted at up to ten sites in the United States.
Currently, hemodialysis, which uses a machine to clean an individual’s blood, is most commonly administered in a dialysis center three times per week. However, an expanding body of scientific literature indicates that clinical outcomes for hemodialysis patients can be improved if treatments are longer in duration, which can be challenging to achieve via in-center dialysis.
During the trial, investigators will measure the safety and performance of the HemoCare Hemodialysis System. In the initial phase of the trial conducted at medical facilities, clinical study participants and their caregivers will receive training on the system and will then transition to home-based dialysis. Primary study endpoints include adverse events as well as regular tests to measure the dose efficacy of dialysis delivered by the device. The HemoCare Hemodialysis System was developed in collaboration with DEKA Research & Development Corporation.
CVS Health is a premier health innovation company helping people on their path to better health. CVS Health has more than 9,900 retail locations, approximately 1,100 walk-in medical clinics, a leading pharmacy benefits manager with approximately 94 million plan members, a dedicated senior pharmacy care business serving more than one million health care consumers per year, and expanding specialty pharmacy services. CVS Health also serves an estimated 38 million people through traditional, voluntary and consumer-directed health insurance products and related services, including a rapidly expanding Medicare Advantage offering and a leading standalone Medicare Part D prescription drug plan.
This was reported by CVS Health on July 17, 2019.
Contact information: Christina Beckerman, Manager, Corporate Communications, CVS Health, 1 CVS Drive, Woonsocket, Rhode Island 02895; 401-770-8868; Email: Christina.Beckerman@CVSHealth.com; Website: www.cvshealth.com